Cat. No.: HY-13514

TG 100713

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

TG 100713 is an inhibitor of PI3K, with IC₅₀s of 24, 50, 165, and 215 nM for PI3Kδ, γ, α and β isoforms respectively.

For research use only. We do not sell to patients.

Purity: 99.21%
CAS No.: 925705-73-3
Formula: C₁₂H₁₀N₆O
Molecular Weight:254.25

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

TG 100713 Chemical Structure

CAS No.: 925705-73-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

TG 100713 is an inhibitor of PI3K, with IC₅₀s of 24, 50, 165, and 215 nM for PI3Kδ, γ, α and β isoforms respectively^[1].

IC₅₀ & Target^[1]

PI3Kδ

24 nM (IC₅₀)

PI3Kγ

50 nM (IC₅₀)

PI3Kα

165 nM (IC₅₀)

PI3Kβ

215 nM (IC₅₀)

All PI3K Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.49 μM Compound: TG100713	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	10.1039/C3MD00301A
HeLa	IC₅₀	0.15 μM Compound: TG100713	Anticancer activity against human HeLa cells by MTT assay Anticancer activity against human HeLa cells by MTT assay	10.1039/C3MD00301A
HepG2	IC₅₀	0.82 μM Compound: TG100713	Anticancer activity against human HepG2 cells by MTT assay Anticancer activity against human HepG2 cells by MTT assay	10.1039/C3MD00301A
MCF7	IC₅₀	1.03 μM Compound: TG100713	Anticancer activity against human MCF7 cells by MTT assay Anticancer activity against human MCF7 cells by MTT assay	10.1039/C3MD00301A

In Vitro

TG100713 (10 μM; 48 or 72 h) strongly inhibits endothelial cell (EC) proliferation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 925705-73-3
Appearance Solid
Molecular Weight 254.25
Formula C₁₂H₁₀N₆O
Color Light yellow to khaki
SMILES

OC1=CC=CC(C2=NC3=C(N)N=C(N)N=C3N=C2)=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Molecules

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]

2020 Apr 23;25(8):1980. PMID: 32340370
Sci Rep

QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using MLR and ANN methods. [Abstract]

2022 Apr 12;12(1):6090. PMID: 35414065

Solvent & Solubility

In Vitro:

DMSO : 6.41 mg/mL (25.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9331 mL

19.6657 mL

39.3314 mL

5 mM

0.7866 mL

3.9331 mL

7.8663 mL

10 mM

0.3933 mL

1.9666 mL

3.9331 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Doukas J, et, al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9331 mL	19.6657 mL	39.3314 mL	98.3284 mL
	5 mM	0.7866 mL	3.9331 mL	7.8663 mL	19.6657 mL
	10 mM	0.3933 mL	1.9666 mL	3.9331 mL	9.8328 mL
	15 mM	0.2622 mL	1.3110 mL	2.6221 mL	6.5552 mL
	20 mM	0.1967 mL	0.9833 mL	1.9666 mL	4.9164 mL
	25 mM	0.1573 mL	0.7866 mL	1.5733 mL	3.9331 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

TG 100713

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) TG 100713

All PI3K Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

TG 100713 Related Classifications

Cat. No.: HY-13514